# Ivermectin Treatment Efficacy in Covid-19 High Risk Patients

> **NCT04920942** · PHASE3 · COMPLETED · sponsor: **Clinical Research Centre, Malaysia** · enrollment: 500 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Ivermectin 0.4mg/kg/day for 5 days

## Key facts

- **NCT ID:** NCT04920942
- **Lead sponsor:** Clinical Research Centre, Malaysia
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-31
- **Primary completion:** 2021-10-31
- **Final completion:** 2021-10-31
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2023-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04920942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04920942, "Ivermectin Treatment Efficacy in Covid-19 High Risk Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04920942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*